FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2766802579> ?p ?o ?g. }

• W2766802579 abstract "Abstract Introduction: Waldenström's macroglobulinemia (WM) is an incurable B-cell lymphoma characterized by the accumulation of IgM-secreting lymphoplasmacytic cells in the bone marrow and other organs. Bortezomib in combination with rituximab and dexamethasone (BDR) is highly active as primary therapy in WM, though treatment-related neuropathy is common with BDR in WM, and often leads to premature treatment discontinuation. Ixazomib is an orally administered proteasome inhibitor with limited neuropathy that is active in myeloma, but has not been previously evaluated in WM Methods: Symptomatic, previously untreated patients with a clinicopathological diagnosis of WM were included in this prospective, single-arm phase II study evaluating ixazomib 4 mg PO on days 1, 8 and 15 + dexamethasone 20 mg PO/IV on days 1, 8 and 15 + rituximab 375 mg/m2 IV on day 1 (IDR) were administered for six 4-week cycles (induction) followed by six 8-week cycles (maintenance). Rituximab was held for the first two cycles of therapy to minimize risk of IgM flare. Zoster prophylaxis and proton pump inhibitors were administered throughout IDR therapy. The study was approved by the institutional review board at the Dana-Farber Cancer Institute, and registered under Clinicaltrials.gov ID NCT02400437. Results: Twenty-six WM patients were enrolled and were exposed to IDR therapy. The median age at WM diagnosis was 63 years (range 46-81 years) and the median age at initiation of therapy was 65 years (range 46-82 years). Baseline median hemoglobin was 10.2 g/dl (range 6.9-13.2 g/dL), median serum IgM level was 5,068 mg/dl (range 653-7,650 mg/dL), 46% of patients had lymphadenopathy and 12% had splenomegaly. The median bone marrow involvement was 55% (range 5-95%). The MYD88 L265P gene mutation was identified in all cases. CXCR4 gene mutations were identified in 15 patients (58%), of whom 10 (67%) had nonsense, and 5 (33%) frameshift mutations. Sixteen patients have completed the induction phase of therapy at this time. Following induction therapy, the median serum IgM level decreased to 2,316 mg/dl (range 287-5,820 mg/dL), median hemoglobin increased to 13.1 mg/dl (range 10.4-14.6 g/dL), and median bone marrow involvement decreased to 23% (range 0-76%). P-value <0.001 for all comparisons against baseline. Using consensus response criteria, the overall response rate was 88% (VGPR 6%, PR 44%, MR 38%) with a major response rate of 50%. Major responses (VGPR + PR) were observed in 47% of patients with CXCR4 mutations versus 64% in those who were wild-type CXCR4 (p=0.32). The median time to response was 8 weeks. The median time to response in CXCR4 mutant patients was 12 weeks versus 8 weeks in wild-type CXCR4 patients (log-rank p=0.03). Four patients have been taken off study; 2 for lack of response, 1 due to lack of clinical benefit with persistent failure to thrive while in PR, and 1 for progressive neuropathy while in PR although in part due to worsening of diabetic neuropathy. No other grade 3 or 4 adverse events were reported. Conclusion: These preliminary data suggest that the combination of IDR is an active and well-tolerated, neuropathy-sparing regimen in symptomatic untreated WM patients. Disclosures Castillo: Biogen: Consultancy; Otsuka: Consultancy; Abbvie: Research Funding; Pharmacyclics: Honoraria; Millennium: Research Funding; Janssen: Honoraria." @default.
• W2766802579 created "2017-11-10" @default.
• W2766802579 creator A5009613920 @default.
• W2766802579 creator A5024726033 @default.
• W2766802579 creator A5026121534 @default.
• W2766802579 creator A5067459987 @default.
• W2766802579 creator A5070629260 @default.
• W2766802579 creator A5081299017 @default.
• W2766802579 creator A5089416977 @default.
• W2766802579 creator A5089994476 @default.
• W2766802579 date "2016-12-02" @default.
• W2766802579 modified "2023-09-29" @default.
• W2766802579 title "Ixazomib, Dexamethasone and Rituximab in Previously Untreated Patients with Waldenström Macroglobulinemia" @default.
• W2766802579 doi "https://doi.org/10.1182/blood.v128.22.2956.2956" @default.
• W2766802579 hasPublicationYear "2016" @default.
• W2766802579 type Work @default.
• W2766802579 sameAs 2766802579 @default.
• W2766802579 citedByCount "4" @default.
• W2766802579 countsByYear W27668025792017 @default.
• W2766802579 countsByYear W27668025792018 @default.
• W2766802579 countsByYear W27668025792020 @default.
• W2766802579 crossrefType "journal-article" @default.
• W2766802579 hasAuthorship W2766802579A5009613920 @default.
• W2766802579 hasAuthorship W2766802579A5024726033 @default.
• W2766802579 hasAuthorship W2766802579A5026121534 @default.
• W2766802579 hasAuthorship W2766802579A5067459987 @default.
• W2766802579 hasAuthorship W2766802579A5070629260 @default.
• W2766802579 hasAuthorship W2766802579A5081299017 @default.
• W2766802579 hasAuthorship W2766802579A5089416977 @default.
• W2766802579 hasAuthorship W2766802579A5089994476 @default.
• W2766802579 hasConcept C126322002 @default.
• W2766802579 hasConcept C141071460 @default.
• W2766802579 hasConcept C2776364478 @default.
• W2766802579 hasConcept C2776391228 @default.
• W2766802579 hasConcept C2777478702 @default.
• W2766802579 hasConcept C2778715236 @default.
• W2766802579 hasConcept C2779338263 @default.
• W2766802579 hasConcept C2780108899 @default.
• W2766802579 hasConcept C2780401358 @default.
• W2766802579 hasConcept C2780653079 @default.
• W2766802579 hasConcept C2781038049 @default.
• W2766802579 hasConcept C2781098529 @default.
• W2766802579 hasConcept C71924100 @default.
• W2766802579 hasConcept C90924648 @default.
• W2766802579 hasConceptScore W2766802579C126322002 @default.
• W2766802579 hasConceptScore W2766802579C141071460 @default.
• W2766802579 hasConceptScore W2766802579C2776364478 @default.
• W2766802579 hasConceptScore W2766802579C2776391228 @default.
• W2766802579 hasConceptScore W2766802579C2777478702 @default.
• W2766802579 hasConceptScore W2766802579C2778715236 @default.
• W2766802579 hasConceptScore W2766802579C2779338263 @default.
• W2766802579 hasConceptScore W2766802579C2780108899 @default.
• W2766802579 hasConceptScore W2766802579C2780401358 @default.
• W2766802579 hasConceptScore W2766802579C2780653079 @default.
• W2766802579 hasConceptScore W2766802579C2781038049 @default.
• W2766802579 hasConceptScore W2766802579C2781098529 @default.
• W2766802579 hasConceptScore W2766802579C71924100 @default.
• W2766802579 hasConceptScore W2766802579C90924648 @default.
• W2766802579 hasLocation W27668025791 @default.
• W2766802579 hasOpenAccess W2766802579 @default.
• W2766802579 hasPrimaryLocation W27668025791 @default.
• W2766802579 hasRelatedWork W1966052157 @default.
• W2766802579 hasRelatedWork W2485213074 @default.
• W2766802579 hasRelatedWork W2515522281 @default.
• W2766802579 hasRelatedWork W2526221777 @default.
• W2766802579 hasRelatedWork W2548001224 @default.
• W2766802579 hasRelatedWork W2550125373 @default.
• W2766802579 hasRelatedWork W2554569362 @default.
• W2766802579 hasRelatedWork W2559274062 @default.
• W2766802579 hasRelatedWork W2562167373 @default.
• W2766802579 hasRelatedWork W2594147984 @default.
• W2766802579 hasRelatedWork W2783355640 @default.
• W2766802579 hasRelatedWork W2924977867 @default.
• W2766802579 hasRelatedWork W2979581330 @default.
• W2766802579 hasRelatedWork W2979698995 @default.
• W2766802579 hasRelatedWork W2979709016 @default.
• W2766802579 hasRelatedWork W2979968335 @default.
• W2766802579 hasRelatedWork W2980272944 @default.
• W2766802579 hasRelatedWork W3028783617 @default.
• W2766802579 hasRelatedWork W3174383617 @default.
• W2766802579 hasRelatedWork W433802874 @default.
• W2766802579 isParatext "false" @default.
• W2766802579 isRetracted "false" @default.
• W2766802579 magId "2766802579" @default.
• W2766802579 workType "article" @default.